October 27, 2005 -- In its first quarter of commercial operations, Amylin Pharmaceuticals produced a larger loss and smaller revenues than analysts expected. The company reported a loss of 65 cents per share on $25.9 million of revenue. The consensus called for a 57 cents per share loss on revenues of $30.7 million. Earlier this year, Amylin scored a rare FDA double approval, receiving final marketing approval for two diabetes drugs in the space of a little over a month. We look at what happened...
